source
- Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancerA recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer. The topline results indicated that the combi…
- BeOne secures FDA approval for lymphoma therapyBeOne received FDA approval for its lymphoma therapy, a notable achievement in a crowded therapeutic area. The agency’s review concluded that the treatment meets safety and efficacy standards, pla…